{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:08:12Z","timestamp":1765544892273,"version":"3.37.3"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T00:00:00Z","timestamp":1675641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T00:00:00Z","timestamp":1675641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Study objectives were to estimate the cumulative incidence of death due to different causes of death (CODs) and investigate the effect of invasive aspergillosis (IA) on each separate COD in a cohort of older patients with acute myeloid leukaemia (AML) or high-risk myelodysplastic syndrome (MDS) included in the Haemato-Oncology Foundation for Adults in the Netherlands (HOVON) 43 randomized controlled trial.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Pre-collected data from the trial was obtained from the HOVON data center and relevant clinical information was extracted. The cumulative incidence of death due to different CODs was estimated with a competing risk model and the association between each COD and prognostic factors, including IA, were investigated with a cause-specific hazard Cox regression model.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total 806 patients were included, mean age of 70\u00a0years and 55% were male. The cumulative incidences of death due to leukaemia or infection at 3, 6, 12 and 36\u00a0months were 0.06, 0.11, 0.23, 0.42 and 0.17, 0.19, 0.22, 0.25 respectively. Incidence of IA was 21% and diagnosis of IA up until the final chemotherapy cycle was associated with an increased risk of dying from leukaemia (cause-specific hazard ratio (<jats:sub>CS<\/jats:sub>HR): 1.75, 95% CI 1.34\u20132.28) and a trend was seen for infection (<jats:sub>CS<\/jats:sub>HR: 1.36, 95% CI 0.96\u20131.91).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Leukaemia was the most likely cause of death over time, however in the first year after diagnosis of AML or high-risk MDS infection was the most likely cause of death. Patients with IA had a relatively increased risk of dying from leukaemia or infection.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-023-08013-5","type":"journal-article","created":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T17:02:51Z","timestamp":1675702971000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effect of invasive aspergillosis on risk for different causes of death in older patients with acute myeloid leukaemia or high-risk myelodysplastic syndrome"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4091-2955","authenticated-orcid":false,"given":"Rebecca","family":"van Grootveld","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Masarotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter A.","family":"von dem Borne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole M. A.","family":"Blijlevens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana A.","family":"Chitu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martha T.","family":"van der Beek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Fiocco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark G. J.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,2,6]]},"reference":[{"key":"8013_CR1","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.jinf.2018.02.012","volume":"76","author":"RJ van de Peppel","year":"2018","unstructured":"van de Peppel RJ, Visser LG, Dekkers OM, de Boer MGJ. The burden of Invasive Aspergillosis in patients with haematological malignancy: a meta-analysis and systematic review. J Infect. 2018;76:550\u201362. https:\/\/doi.org\/10.1016\/j.jinf.2018.02.012.","journal-title":"J Infect"},{"key":"8013_CR2","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.2165\/00003495-200767110-00004","volume":"67","author":"G Maschmeyer","year":"2007","unstructured":"Maschmeyer G, Haas A, Cornely OA. Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. Drugs. 2007;67:1567\u2013601. https:\/\/doi.org\/10.2165\/00003495-200767110-00004.","journal-title":"Drugs"},{"key":"8013_CR3","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/j.1365-2141.2007.06812.x","volume":"139","author":"PD Barnes","year":"2007","unstructured":"Barnes PD, Marr KA. Risks, diagnosis and outcomes of invasive fungal infections in haematopoietic stem cell transplant recipients. Br J Haematol. 2007;139:519\u201331. https:\/\/doi.org\/10.1111\/j.1365-2141.2007.06812.x.","journal-title":"Br J Haematol"},{"key":"8013_CR4","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1086\/605665","volume":"49","author":"C Girmenia","year":"2009","unstructured":"Girmenia C, Barosi G, Aversa F, Bacigalupo A, Barbui T, Baronciani D, et al. Prophylaxis and treatment of invasive fungal diseases in allogeneic stem cell transplantation: results of a consensus process by Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Clin Infect Dis. 2009;49:1226\u201336. https:\/\/doi.org\/10.1086\/605665.","journal-title":"Clin Infect Dis"},{"key":"8013_CR5","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3109\/13693786.2011.557668","volume":"49","author":"M Michallet","year":"2011","unstructured":"Michallet M, Sobh M, Morisset S, Kraghel S, Nicolini FE, Thomas X, et al. Risk factors for invasive aspergillosis in acute myeloid leukemia patients prophylactically treated with posaconazole. Med Mycol. 2011;49:681\u20137. https:\/\/doi.org\/10.3109\/13693786.2011.557668.","journal-title":"Med Mycol"},{"key":"8013_CR6","doi-asserted-by":"publisher","first-page":"4179","DOI":"10.1182\/blood-2008-07-172007","volume":"113","author":"G Juliusson","year":"2009","unstructured":"Juliusson G, Antunovic P, Derolf A, Lehmann S, M\u00f6llg\u00e5rd L, Stockelberg D, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113:4179\u201387. https:\/\/doi.org\/10.1182\/blood-2008-07-172007.","journal-title":"Blood"},{"key":"8013_CR7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/leu.2015.188","volume":"30","author":"AG Dinmohamed","year":"2016","unstructured":"Dinmohamed AG, Visser O, van Norden Y, Blijlevens NM, Cornelissen JJ, Huls GA, et al. Treatment, trial participation and survival in adult acute myeloid leukemia: a population-based study in the Netherlands, 1989\u20132012. Leukemia. 2016;30:24\u201331. https:\/\/doi.org\/10.1038\/leu.2015.188.","journal-title":"Leukemia"},{"key":"8013_CR8","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1016\/j.ejca.2015.08.003","volume":"51","author":"R De Angelis","year":"2015","unstructured":"De Angelis R, Minicozzi P, Sant M, Dal Maso L, Brewster DH, Osca-Gelis G, et al. Survival variations by country and age for lymphoid and myeloid malignancies in Europe 2000\u20132007: Results of EUROCARE-5 population-based study. Eur J Cancer. 2015;51:2254\u201368. https:\/\/doi.org\/10.1016\/j.ejca.2015.08.003.","journal-title":"Eur J Cancer"},{"key":"8013_CR9","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/s0145-2126(01)00005-4","volume":"25","author":"AM Stalfelt","year":"2001","unstructured":"Stalfelt AM, Brodin H, Pettersson S, Ekl\u00f6f A. The final phase in acute myeloid leukaemia (AML): a study of cause of death, place of death and type of care during the last week of life. Leuk Res. 2001;25:673\u201380. https:\/\/doi.org\/10.1016\/s0145-2126(01)00005-4.","journal-title":"Leuk Res"},{"key":"8013_CR10","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s10096-011-1397-5","volume":"31","author":"M Michallet","year":"2012","unstructured":"Michallet M, B\u00e9net T, Sobh M, Kraghel S, El Hamri M, Cannas G, et al. Invasive aspergillosis: an important risk factor on the short- and long-term survival of acute myeloid leukemia (AML) patients. Eur J Clin Microbiol Infect Dis. 2012;31:991\u20137. https:\/\/doi.org\/10.1007\/s10096-011-1397-5.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"8013_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00520-014-2333-x","volume":"23","author":"HW Cheng","year":"2015","unstructured":"Cheng HW, Li CW, Chan KY, Au HY, Chan PF, Sin YC, et al. End-of-life characteristics and palliative care provision for elderly patients suffering from acute myeloid leukemia. Support Care Cancer. 2015;23:111\u20136. https:\/\/doi.org\/10.1007\/s00520-014-2333-x.","journal-title":"Support Care Cancer"},{"key":"8013_CR12","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1513\/annalsats.201304-097oc","volume":"10","author":"JB Garcia","year":"2013","unstructured":"Garcia JB, Lei X, Wierda W, Cortes JE, Dickey BF, Evans SE, et al. Pneumonia during remission induction chemotherapy in patients with acute leukemia. Ann Am Thorac Soc. 2013;10:432\u201340. https:\/\/doi.org\/10.1513\/annalsats.201304-097oc.","journal-title":"Ann Am Thorac Soc"},{"key":"8013_CR13","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1056\/nejmoa0901409","volume":"361","author":"B L\u00f6wenberg","year":"2009","unstructured":"L\u00f6wenberg B, Ossenkoppele GJ, van Putten W, Schouten HC, Graux C, Ferrant A, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361:1235\u201348. https:\/\/doi.org\/10.1056\/nejmoa0901409.","journal-title":"N Engl J Med"},{"key":"8013_CR14","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1182\/blood.V126.23.3318.3318","volume":"126","author":"J Foster","year":"2015","unstructured":"Foster J, Blonquist TM, El-Jawahri A, Fathi AT, Amrein PC, Sadrzadeh H, et al. The End of life for patients with acute myeloid leukemia (AML)\u2014a single center experience. Blood. 2015;126:3318. https:\/\/doi.org\/10.1182\/blood.V126.23.3318.3318.","journal-title":"Blood"},{"key":"8013_CR15","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1093\/mmy\/myu036","volume":"52","author":"RJ van de Peppel","year":"2014","unstructured":"van de Peppel RJ, Dekkers OM, von dem Borne PA, de Boer MG. Relapsed and secondary disease drive the risk profile for invasive aspergillosis prior to stem cell transplantation in patients with acute myeloid leukemia or myelodysplastic syndrome. Med Mycol. 2014;52:699\u2013705. https:\/\/doi.org\/10.1093\/mmy\/myu036.","journal-title":"Med Mycol"},{"key":"8013_CR16","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/bmt.2017.71","volume":"52","author":"RJ van de Peppel","year":"2017","unstructured":"van de Peppel RJ, von dem Borne PA, le Cessie S, de Boer MGJ. A new time-dependent approach for assessment of the impact of invasive aspergillosis shows effect on short- but not on long-term survival of patients with AML or high-risk MDS. Bone Marrow Transplant. 2017;52:883\u20138. https:\/\/doi.org\/10.1038\/bmt.2017.71.","journal-title":"Bone Marrow Transplant"},{"key":"8013_CR17","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","volume":"36","author":"RM Shallis","year":"2019","unstructured":"Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 2019;36:70\u201387. https:\/\/doi.org\/10.1016\/j.blre.2019.04.005.","journal-title":"Blood Rev"},{"key":"8013_CR18","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/s41408-017-0011-1","volume":"7","author":"S Bertoli","year":"2017","unstructured":"Bertoli S, Tavitian S, Huynh A, Borel C, Guenounou S, Luquet I, et al. Improved outcome for AML patients over the years 2000\u20132014. Blood Cancer J. 2017;7:635. https:\/\/doi.org\/10.1038\/s41408-017-0011-1.","journal-title":"Blood Cancer J"},{"key":"8013_CR19","doi-asserted-by":"publisher","first-page":"3334","DOI":"10.3390\/cancers12113334","volume":"12","author":"SM Ramadan","year":"2020","unstructured":"Ramadan SM, Suciu S, Stevens-Kroef M, Willemze R, Amadori S, de Witte T, et al. Survival improvement over Time of 960 s-AML patients included in 13 EORTC-GIMEMA-HOVON trials. Cancers (Basel). 2020;12:3334. https:\/\/doi.org\/10.3390\/cancers12113334.","journal-title":"Cancers (Basel)"},{"key":"8013_CR20","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","volume":"107","author":"FR Appelbaum","year":"2006","unstructured":"Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, et al. Age and acute myeloid leukemia. Blood. 2006;107:3481\u20135. https:\/\/doi.org\/10.1182\/blood-2005-09-3724.","journal-title":"Blood"},{"key":"8013_CR21","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424\u201347. https:\/\/doi.org\/10.1182\/blood-2016-08-733196.","journal-title":"Blood"},{"key":"8013_CR22","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/s1473-3099(02)00437-1","volume":"2","author":"G Gavazzi","year":"2002","unstructured":"Gavazzi G, Krause KH. Ageing and infection. Lancet Infect Dis. 2002;2:659\u201366. https:\/\/doi.org\/10.1016\/s1473-3099(02)00437-1.","journal-title":"Lancet Infect Dis"},{"key":"8013_CR23","doi-asserted-by":"publisher","first-page":"277","DOI":"10.14336\/ad.2020.0627","volume":"12","author":"W He","year":"2021","unstructured":"He W, Xiao K, Fang M, Xie L. Immune cell number, phenotype, and function in the elderly with sepsis. Aging Dis. 2021;12:277\u201396. https:\/\/doi.org\/10.14336\/ad.2020.0627.","journal-title":"Aging Dis"},{"key":"8013_CR24","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","volume":"71","author":"JP Donnelly","year":"2020","unstructured":"Donnelly JP, Chen SC, Kauffman CA, Steinbach WJ, Baddley JW, Verweij PE, et al. Revision and update of the consensus definitions of invasive fungal disease from the european organization for research and treatment of cancer and the mycoses study group education and research consortium. Clin Infect Dis. 2020;71:1367\u201376. https:\/\/doi.org\/10.1093\/cid\/ciz1008.","journal-title":"Clin Infect Dis"},{"key":"8013_CR25","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1002\/sim.2712","volume":"26","author":"H Putter","year":"2007","unstructured":"Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med. 2007;26:2389\u2013430. https:\/\/doi.org\/10.1002\/sim.2712.","journal-title":"Stat Med"},{"key":"8013_CR26","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR. Regression models and life-tables. J Roy Stat Soc: Ser B (Methodol). 1972;34:187\u2013220. https:\/\/doi.org\/10.1111\/j.2517-6161.1972.tb00899.x.","journal-title":"J Roy Stat Soc: Ser B (Methodol)"},{"key":"8013_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v038.i07","volume":"38","author":"LC Wreede","year":"2011","unstructured":"Wreede LC, Fiocco M, Putter H. mstate: an R package for the analysis of competing risks and multi-state models. J Stat Softw. 2011;38:1\u201330. https:\/\/doi.org\/10.18637\/jss.v038.i07.","journal-title":"J Stat Softw"},{"key":"8013_CR28","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.leukres.2014.01.007","volume":"38","author":"C Girmenia","year":"2014","unstructured":"Girmenia C, Micozzi A, Piciocchi A, Gentile G, Di Caprio L, Nasso D, et al. Invasive fungal diseases during first induction chemotherapy affect complete remission achievement and long-term survival of patients with acute myeloid leukemia. Leuk Res. 2014;38:469\u201374. https:\/\/doi.org\/10.1016\/j.leukres.2014.01.007.","journal-title":"Leuk Res"},{"key":"8013_CR29","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1056\/nejmra0808853","volume":"360","author":"BH Segal","year":"2009","unstructured":"Segal BH. Aspergillosis. N Engl J Med. 2009;360:1870\u201384. https:\/\/doi.org\/10.1056\/nejmra0808853.","journal-title":"N Engl J Med."},{"key":"8013_CR30","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1093\/cid\/ciy698","volume":"68","author":"RJ van de Peppel","year":"2019","unstructured":"van de Peppel RJ, de Boer MGJ. The complex case of aspergillus and mortality. Clin Infect Dis. 2019;68:531\u20132. https:\/\/doi.org\/10.1093\/cid\/ciy698.","journal-title":"Clin Infect Dis"},{"key":"8013_CR31","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1200\/jco.18.00374","volume":"36","author":"RA Taplitz","year":"2018","unstructured":"Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. J Clin Oncol. 2018;36:3043\u201354. https:\/\/doi.org\/10.1200\/jco.18.00374.","journal-title":"J Clin Oncol"},{"key":"8013_CR32","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.1093\/jac\/dky286","volume":"73","author":"JA Maertens","year":"2018","unstructured":"Maertens JA, Girmenia C, Br\u00fcggemann RJ, Duarte RF, Kibbler CC, Ljungman P, et al. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. J Antimicrob Chemother. 2018;73:3221\u201330. https:\/\/doi.org\/10.1093\/jac\/dky286.","journal-title":"J Antimicrob Chemother."},{"key":"8013_CR33","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","volume":"63","author":"TF Patterson","year":"2016","unstructured":"Patterson TF, Thompson GR, Denning DW, Fishman JA, Hadley S, Herbrecht R, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63:e1\u201360. https:\/\/doi.org\/10.1093\/cid\/ciw326.","journal-title":"Clin Infect Dis"},{"key":"8013_CR34","unstructured":"SWAB Invasive Fungal Infections Guidelines Committee (2017) SWAB Guidelines for the Management of Invasive Fungal Infections. Dutch Working Party on Antibiotic Policy (SWAB). https:\/\/swab.nl\/nl\/invasieve-schimmelinfecties. Accessed 14 Dec 2017."},{"key":"8013_CR35","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1093\/jac\/dky550","volume":"74","author":"MI Del Principe","year":"2019","unstructured":"Del Principe MI, Dragonetti G, Verga L, Candoni A, Marchesi F, Cattaneo C, et al. \u201cReal-life\u201d analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study. J Antimicrob Chemother. 2019;74:1062\u20138. https:\/\/doi.org\/10.1093\/jac\/dky550.","journal-title":"J Antimicrob Chemother"},{"key":"8013_CR36","doi-asserted-by":"publisher","first-page":"644","DOI":"10.3324\/haematol.2009.012054","volume":"95","author":"L Pagano","year":"2010","unstructured":"Pagano L, Caira M, Candoni A, Offidani M, Martino B, Specchia G, et al. Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica. 2010;95:644\u201350. https:\/\/doi.org\/10.3324\/haematol.2009.012054.","journal-title":"Haematologica"},{"key":"8013_CR37","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1086\/343804","volume":"186","author":"J Maertens","year":"2002","unstructured":"Maertens J, Van Eldere J, Verhaegen J, Verbeken E, Verschakelen J, Boogaerts M. Use of circulating galactomannan screening for early diagnosis of invasive aspergillosis in allogeneic stem cell transplant recipients. J Infect Dis. 2002;186:1297\u201313061. https:\/\/doi.org\/10.1086\/343804.","journal-title":"J Infect Dis"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08013-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-023-08013-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08013-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T17:03:35Z","timestamp":1675703015000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-023-08013-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,6]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["8013"],"URL":"https:\/\/doi.org\/10.1186\/s12879-023-08013-5","relation":{},"ISSN":["1471-2334"],"issn-type":[{"type":"electronic","value":"1471-2334"}],"subject":[],"published":{"date-parts":[[2023,2,6]]},"assertion":[{"value":"15 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All ethical considerations in this post-hoc study were within the intended use of the HOVON-43 randomized controlled trial and in accordance to the ethical principles as posed in the declaration of Helsinki as well as current national legislation. The HOVON-43 study was approved by the ethics committee of the Erasmus University Rotterdam\/Academic Hospital Rotterdam (METC EUR\/AZR, 30 August 2000) and the ethics committee of each participating institution () []. Written informed consent was originally obtained from the participants for the HOVON-43 study for which the data were collected.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No potential financial or non-financial competing interest was reported by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"78"}}